1-20 of 431
Marina Konopleva, MD PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

The Combined Treatment with the FLT3-Inhibitor AC220 and the Complex I Inhibitor Iacs-010759 Synergistically Depletes Wt- and FLT3-Mutated Acute Myeloid Leukemia Cells

Xiyuan Lu, Alessia Lodi, PhD, Lina Han, PhD, Joseph R Marszalek, PhD, Marina Konopleva, MD PhD, Stefano Tiziani, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
DOI: https://doi.org/10.1182/blood-2020-141986
Published: 2020
Journal Articles

Response and Survival Outcomes with Hypomethylating Agents in Patients with Chronic Myelomonocytic Leukemia Based on Disease Phenotype and Risk Categories

Jorge M. Ramos Perez, Veronica A Guerra, MD, Danielle Hammond, MD, Kelly S. Chien, MD, Rashmi Kanagal-Shamanna, MD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Shilpa Paul, PharmD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Marina Konopleva, MD PhD, Naval Daver, MD, Farhad Ravandi, MBBS, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Koichi Takahashi, MD PhD, Zeev E. Estrov, MD, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Guillermo Montalban-Bravo, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–9.
DOI: https://doi.org/10.1182/blood-2020-142469
Published: 2020
Journal Articles

Outcomes of Chronic Myelomonocytic Leukemia (CMML) after Hypomethylating Agent (HMA) Failure

Veronia Guerra, Jorge M. Ramos Perez, MD, Danielle Hammond, MD, Kelly S. Chien, MD, Rashmi Kanagal-Shamanna, MD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Shilpa Paul, PharmD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Marina Konopleva, MD PhD, Naval Daver, MD, Farhad Ravandi, MBBS, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Ghayas C. Issa, MD, Koichi Takahashi, MD PhD, Zeev E. Estrov, MD, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD, Guillermo Montalban Bravo, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
DOI: https://doi.org/10.1182/blood-2020-139901
Published: 2020
Journal Articles

Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia

Guillermo Montalban Bravo, MD, Rashmi Kanagal-Shamanna, MD, Veronia Guerra, Jorge M. Ramos Perez, MD, Danielle Hammond, MD, Shilpa Paul, PharmD, Kiran Naqvi, MD MPH, Koji Sasaki, MD, Elias Jabbour, MD, Courtney D. DiNardo, MD MSCE, Koichi Takahashi, MD PhD, Marina Konopleva, MD PhD, Naveen Pemmaraju, MD, Tapan M. Kadia, MD, Farhad Ravandi, MBBS, Naval Daver, MD, Gautam Borthakur, MD, Zeev E. Estrov, MD, Joseph D. Khoury, MD, Sanam Loghavi, MD, Sherry A. Pierce, BSN, BA, Carlos E. Bueso-Ramos, MD PhD, Keyur Patel, MD PhD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–29.
DOI: https://doi.org/10.1182/blood-2020-137212
Published: 2020
Journal Articles

Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL): Focus on MRD Results

Nitin Jain, MD, Michael J. Keating, MBBS, Philip A. Thompson, MB, MS, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Gautam Borthakur, MD, Koichi Takahashi, MD PhD, Zeev E. Estrov, MD, Koji Sasaki, MD, Nathan H Fowler, MD, Tapan M. Kadia, MD, Marina Konopleva, MD PhD, Yesid Alvarado, MD, Musa Yilmaz, MD, Courtney D. DiNardo, MD MSCE, Prithviraj Bose, MD, Maro Ohanian, DO, Naveen Pemmaraju, MD, Elias Jabbour, MD, Rashmi Kanagal-Shamanna, MD, Keyur Patel, MD PhD, Wei Wang, MD PhD, Jeffrey L. Jorgensen, MD PhD, Sa A Wang, MD, Naveen Garg, MD, Xuemei Wang, MS, Chongjuan Wei, PhD, Nichole Cruz, RN, Ana Ayala, RN, William Plunkett, PhD, Hagop M. Kantarjian, MD, Varsha Gandhi, PhD, William G. Wierda, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 42–43.
DOI: https://doi.org/10.1182/blood-2020-142014
Published: 2020
Journal Articles

Impact of Cytogenetic Abnormalities (CA) on Outcome of Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, C. Cameron Yin, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Koichi Takahashi, MD PhD, Bouthaina S. Dabaja, MD, Srdan Verstovsek, MD PhD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Caitlin R. Rausch, PharmD, Guillermo Garcia-Manero, MD, William G. Wierda, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Patrice Nasnas, MD, Rita Khouri, Monica Kwari, BSN, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–47.
DOI: https://doi.org/10.1182/blood-2020-143401
Published: 2020
Journal Articles

Interim Results of an Open-Label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-PDL1 Mab, Smoothened Inhibitor, Anti-CD33 Mab, Bcl-2 Inhibitor, and Azacitidine As Single-Agents and As Combinations for Relapsed/Refractory Acute Myeloid Leukemia

Nicholas J. Short, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Koji Sasaki, MD, Ghayas C. Issa, MD, Guillermo Montalban-Bravo, MD, Prithviraj Bose, MD, Jan A. Burger, MD PhD, Darla Miller, Lynette Alexander-Williams, Farhad Ravandi, MBBS, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Naval Daver, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 21–23.
DOI: https://doi.org/10.1182/blood-2020-140153
Published: 2020
Journal Articles

Implications of RAS Mutational Status in Subsets of Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) across Therapy Groups

Daniel Rivera, MD, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Marina Konopleva, MD PhD, Rashmi Kanagal-Shamanna, MD, Naveen Pemmaraju, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Koichi Takahashi, MD PhD, Elias Jabbour, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Sherry A. Pierce, BSN, BA, Michael Andreeff, MD PhD, Kapil N. Bhalla, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MBBS, Tapan M. Kadia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20–22.
DOI: https://doi.org/10.1182/blood-2020-142043
Published: 2020
Journal Articles

Cigarette Smoke or Cigarette Condensate Exposure Enhances Growth of FLT3-ITD AML Models and Alters DNA Methylation and Leukemic Gene Expression

Mary Figueroa, BS, Maninder Khosla, BS, Yue Lu, PhD, Marcos Estecio, PhD, Seyed Javad Moghaddam, MD, Elias Jabbour, MD, Marina Konopleva, MD PhD, Courtney D. DiNardo, MD MSCE, Joya Chandra, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 29–30.
DOI: https://doi.org/10.1182/blood-2020-142478
Published: 2020
Journal Articles

Cytopenia Management in Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax Plus Azacitidine in the VIALE-A Study

Keith W. Pratz, MD, Courtney D. DiNardo, MD MSCE, Dominik Selleslag, MD, Junmin Li, Kazuhito Yamamoto, MD PhD, Marina Konopleva, MD PhD, Andrew McDonald, Sunil Babu, Don A. Stevens, MD, Hagop M. Kantarjian, MD, Fabiola Traina, MD PhD, Adriano Venditti, MD, Jiri Mayer, MD, Melissa Montez, Giridharan Ramsingh, MD, Huan Jin, William Ainsworth, Yinghui Duan, PhD, Anders Erik Svensson, MD, Michael Werner, Jalaja Potluri, MD, Brian A Jonas, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 51–53.
DOI: https://doi.org/10.1182/blood-2020-134832
Published: 2020
Journal Articles

Venetoclax, FLT3 Inhibitor and Decitabine in FLT3 mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial

Abhishek Maiti, MBBS, Courtney D. DiNardo, MD MSCE, Farhad Ravandi, MBBS, Naveen Pemmaraju, MD, Gautam Borthakur, MD, Prithviraj Bose, MD, Ghayas C. Issa, MD, Tapan M. Kadia, MD, Nicholas J. Short, MD, Musa Yilmaz, MD, Guillermo Montalban-Bravo, MD, Alessandra Ferrajoli, MD, Elias Jabbour, MD, Nitin Jain, MD, Maro Ohanian, DO, Koichi Takahashi, MD PhD, Philip A. Thompson, MB, MS, Caitlin R. Rausch, PharmD, Kathryn S Montalbano, RN, Sherry A. Pierce, BSN, BA, Hagop M. Kantarjian, MD, Naval Daver, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 53–55.
DOI: https://doi.org/10.1182/blood-2020-137822
Published: 2020
Journal Articles

AML Cells Alter Bone Homeostasis By Promoting the Formation of Immature Bone and Resorption of Mature Bone That Supports Leukemia Progression

Anudishi Tyagi, PhD, Bin Yuan, Stanley Ly, Fouad El-Dana, MD, Vinitha Mary Kuruvilla, MSc, Qi Zhang, PhD, Christine B Peterson, Xin Zhou, PhD, Benoit deCrombrugghe, Michael Andreeff, MD PhD, Marina Konopleva, MD PhD, Behrang Amini, MD PhD, Venkata Lokesh Battula, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 27.
DOI: https://doi.org/10.1182/blood-2020-142777
Published: 2020
Journal Articles

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response

Naval Daver, MD, Sreyashi Basu, PhD, Guillermo Garcia-Manero, MD, Hussein A Abbas, MDPhD, Marina Konopleva, MD PhD, Tapan M. Kadia, MD, Courtney D. DiNardo, MD MSCE, Gautam Borthakur, MD, Ahmad S. Alotaibi, MD, Naveen Pemmaraju, MD, Elias Jabbour, MD, Sherry A. Pierce, BSN, BA, Mark Brandt, BS, Koichi Takahashi, MD PhD, Jing Ning, Steven M. Kornblau, MD, Koji Sasaki, MD, Musa Yilmaz, MD, Ghayas C. Issa, MD, Nicholas J. Short, MD, Jairo A. Matthews, Wilmer Flores, Michael Andreeff, MD PhD, Jorge E. Cortes, MD, Farhad Ravandi, MBBS, James P Allison, PhD, Hagop M. Kantarjian, MD, Padmanee Sharma
Journal: Blood
Blood (2020) 136 (Supplement 1): 43–45.
DOI: https://doi.org/10.1182/blood-2020-142824
Published: 2020
Journal Articles

CD22 Expression Level As a Predictor of Survival in Patients (Pts) with Relapsed/Refractory (R-R) Acute Lymphoblastic Leukemia (ALL) Treated with Inotuzumab Ozogamicin (INO) in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) with or without Blinatumomab: Results from a Phase 2 Study

Hind Rafei, MD, Hagop M. Kantarjian, MD, Koji Sasaki, MD, Nicholas J. Short, MD, Farhad Ravandi, MBBS, Xuelin Huang, PhD, Joseph D. Khoury, MD, Sa A Wang, MD, Jeffrey L. Jorgensen, MD PhD, Issa F. Khouri, MD, Partow Kebriaei, MD, Nitin Jain, MD, Bouthaina S. Dabaja, MD, Lucia Masarova, MD, Tapan M. Kadia, MD, Shilpa Paul, PharmD, Dan Nichols, Guillermo Garcia-Manero, MD, Jan A. Burger, MD PhD, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Guillermo Montalban-Bravo, MD, Musa Yilmaz, MD, Prithviraj Bose, MD, Rita Khouri, Philip A. Thompson, MB, MS, Jovitta Jacob, Meagan Rostykus, RN, Rebecca Garris, MSc, Marina Konopleva, MD PhD, Susan M. O'Brien, MD, Elias Jabbour, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–25.
DOI: https://doi.org/10.1182/blood-2020-143400
Published: 2020
Journal Articles

The Novel Dihydroorotate Dehydrogenase (DHODH) Inhibitor PTC299 Inhibit De Novo Pyrimidine Synthesis with Broad Anti-Leukemic Activity Against Acute Myeloid Leukemia

Sujan Piya, PhD, Marla Weetall, PhD, Josephine Sheedy, BS, MSc, Balmiki Ray, PhD, Huaxian Ma, MS, Kensuke Kojima, MD PhD, Vivian Ruvolo, MS, Mahesh Basyal, BS, Marina Konopleva, MD PhD, Michael Andreeff, MD PhD, Gautam Borthakur, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 8–9.
DOI: https://doi.org/10.1182/blood-2020-139940
Published: 2020
Journal Articles

"Triple" Combination of Targeting Methyltransferase, BCL-2 and PD-1 Facilitates Therapeutic Responses in Acute Myeloid Leukemia (AML)

Zhihong Zeng, MD, Shelley Herbrich, PhD, Tianyu Cai, PhD, Antonio Cavazos, MSc, Taylor Manzella, Helen Ma, MS, Vinitha Mary Kuruvilla, MSc, Kala Hayes, Jairo A. Matthews, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
DOI: https://doi.org/10.1182/blood-2020-142031
Published: 2020
Journal Articles

The Direct Interactions with Bone Marrow Microenvironment Confer Resistance to the Inhibition of Oxidative Phosphorylation in AML

Yoko Tabe, MD PhD, Kaori Saito, Kotoko Yamatani, MD, Haeun Yang, Rodrigo Jacamo, PhD, Helen Ma, MS, Vivian Ruvolo, MS, Qi Zhang, PhD, Vinitha Mary Kuruvilla, MSc, Natalia Baran, PhDMD, Junichi Imoto, Kazuho Ikeo, PhD, Koya Suzuki, PhD, Takashi Miida, MD PhD, Michael Andreeff, MD PhD, Christopher P Vellano, Joseph R Marszalek, PhD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11.
DOI: https://doi.org/10.1182/blood-2020-137366
Published: 2020
Journal Articles

Liposomal Cytarabine and Daunorubicin (CPX-351) in Combination with Gemtuzumab Ozogamicin (GO) in Relapsed Refractory (R/R) Patients with Acute Myeloid Leukemia (AML) and Post-Hypomethylating Agent (Post-HMA) Failure High-Risk Myelodysplastic Syndrome (HR-MDS)

Jorge M. Ramos Perez, Tapan M. Kadia, MD, Guillermo Montalban-Bravo, MD, Stefan Faderl, MD, Koji Sasaki, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Lucia Masarova, MD, Alessandra Ferrajoli, MD, Elias Jabbour, MD, Gautham Borthakur, Hind Al Azzawi, Naveen Pemmaraju, MD, Marina Konopleva, MD PhD, Sherry A. Pierce, BSN, BA, Guillermo Garcia-Manero, MD, Michael Andreeff, MD PhD, Hagop M. Kantarjian, MD, Farhad Ravandi, MBBS, Yesid Alvarado, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 32–34.
DOI: https://doi.org/10.1182/blood-2020-142570
Published: 2020
Journal Articles

Predictors of Early Mortality, Response, and Survival in Newly Diagnosed Acute Myeloid Leukemia (AML) Using a Contemporary Academic Cohort

Patrick K Reville, MD, Graciela M. Nogueras González, MPH, Farhad Ravandi, MBBS, Koji Sasaki, MD, Gautam Borthakur, MD, Guillermo Garcia-Manero, MD, Naval Daver, MD, Courtney D. DiNardo, MD MSCE, Elias Jabbour, MD, Naveen Pemmaraju, MD, Michael Andreeff, MD PhD, Srdan Verstovsek, MD PhD, Alessandra Ferrajoli, MD, Nitin Jain, MD, Maro Ohanian, DO, Sherry A. Pierce, BSN, BA, Zeev E. Estrov, MD, Marina Konopleva, MD PhD, Hagop M. Kantarjian, MD, Tapan M. Kadia, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 44–45.
DOI: https://doi.org/10.1182/blood-2020-141837
Published: 2020
Journal Articles

Risk of Gvhd and Survival in Patients with Acute Leukemia Who Were Bridged to Allogeneic Stem Cell Transplantation (alloSCT) with Venetoclax- Based Therapy

Akash Mukherjee, Denái R. Milton, MS, Elias Jabbour, MD, Naval Daver, MD, Alison Gulbis, Celina Ledesma, Marina Konopleva, MD PhD, Courtney D. DiNardo, MD MSCE, Farhad Ravandi, MBBS, Tapan M. Kadia, MD, Gheath Alatrash, Amin M. Alousi, MD, May Daher, David Marin, Amanda L. Olson, Betul Oran, MDMS, Partow Kebriaei, MD, Neeraj Saini, MD, Samer A. Srour, MD MS, Uday R. Popat, MD, Jin S. Im, Rohtesh Mehta, Gabriela Rondon, Hagop M. Kantarjian, MD, Richard E. Champlin, MD, Issa F. Khouri, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 13–14.
DOI: https://doi.org/10.1182/blood-2020-137097
Published: 2020